Literature DB >> 15773903

Astrocyte activation by fibroblast growth factor-1 and motor neuron apoptosis: implications for amyotrophic lateral sclerosis.

Patricia Cassina1, Mariana Pehar, Marcelo R Vargas, Raquel Castellanos, Ana G Barbeito, Alvaro G Estévez, John A Thompson, Joseph S Beckman, Luis Barbeito.   

Abstract

Fibroblast growth factor-1 (FGF1 or acidic FGF) is highly expressed in motor neurons. FGF-1 is released from cells by oxidative stress, which might occur from SOD-1 aberrant function in amyotrophic lateral sclerosis (ALS). Although FGF-1 is known to be neuroprotective after spinal cord injury or axotomy, we found that FGF-1 could activate spinal cord astrocytes in a manner that decreased motor neuron survival in co-cultures. FGF-1 induced accumulation of the FGF receptor 1 (FGFR1) in astrocyte nuclei and potently stimulated nerve growth factor (NGF) expression and secretion. The FGFR1 tyrosine kinase inhibitor PD166866 prevented these effects. Previously, we have shown that NGF secretion by reactive astrocytes induces motor neuron apoptosis through a p75(NTR)-dependent mechanism. Embryonic motor neurons co-cultured on the top of astrocytes exhibiting activated FGFR1 underwent apoptosis, which was prevented by PD166866 or by adding either anti-NGF or anti-p75(NTR) neutralizing antibodies. In the degenerating spinal cord of mice carrying the ALS mutation G93A of Cu, Zn superoxide dismutase, FGF-1 was no longer localized only in the cytosol of motor neurons, while FGFR1 accumulated in the nuclei of reactive astrocytes. These results suggest that FGF-1 released by oxidative stress from motor neurons might have a role in activating astrocytes, which could in turn initiate motor neuron apoptosis in ALS through a p75(NTR)-dependent mechanism.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15773903     DOI: 10.1111/j.1471-4159.2004.02984.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  39 in total

1.  Human stem cell-derived spinal cord astrocytes with defined mature or reactive phenotypes.

Authors:  Nuno J Lamas; Alejandro D Garcia; Laurent Roybon; Eun Ju Yang; Rita Sattler; Vernice J Lewis; Yoon A Kim; C Alan Kachel; Jeffrey D Rothstein; Serge Przedborski; Hynek Wichterle; Christopher E Henderson
Journal:  Cell Rep       Date:  2013-08-29       Impact factor: 9.423

2.  Astrocyte and muscle-derived secreted factors differentially regulate motoneuron survival.

Authors:  Anna R Taylor; David J Gifondorwa; Jason M Newbern; Mac B Robinson; Jane L Strupe; David Prevette; Ronald W Oppenheim; Carolanne E Milligan
Journal:  J Neurosci       Date:  2007-01-17       Impact factor: 6.167

Review 3.  A role for copper in the toxicity of zinc-deficient superoxide dismutase to motor neurons in amyotrophic lateral sclerosis.

Authors:  Kari A Trumbull; Joseph S Beckman
Journal:  Antioxid Redox Signal       Date:  2009-07       Impact factor: 8.401

Review 4.  Astrocyte, the star avatar: redefined.

Authors:  Pankaj Seth; Nitin Koul
Journal:  J Biosci       Date:  2008-09       Impact factor: 1.826

Review 5.  Renal senescence in 2008: progress and challenges.

Authors:  Xin J Zhou; Ramesh Saxena; Zhihong Liu; N D Vaziri; Fred G Silva
Journal:  Int Urol Nephrol       Date:  2008-06-27       Impact factor: 2.370

6.  Glia as primary drivers of neuropathology in TDP-43 proteinopathies.

Authors:  Steven A Sloan; Ben A Barres
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-07       Impact factor: 11.205

7.  Necroptosis drives motor neuron death in models of both sporadic and familial ALS.

Authors:  Diane B Re; Virginia Le Verche; Changhao Yu; Mackenzie W Amoroso; Kristin A Politi; Sudarshan Phani; Burcin Ikiz; Lucas Hoffmann; Martijn Koolen; Tetsuya Nagata; Dimitra Papadimitriou; Peter Nagy; Hiroshi Mitsumoto; Shingo Kariya; Hynek Wichterle; Christopher E Henderson; Serge Przedborski
Journal:  Neuron       Date:  2014-02-06       Impact factor: 17.173

8.  Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis.

Authors:  Marcelo R Vargas; Delinda A Johnson; Daniel W Sirkis; Albee Messing; Jeffrey A Johnson
Journal:  J Neurosci       Date:  2008-12-10       Impact factor: 6.167

9.  Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand?

Authors:  Alexandre Henriques; Claudia Pitzer; Armin Schneider
Journal:  Front Neurosci       Date:  2010-06-11       Impact factor: 4.677

10.  The synthetic inhibitor of fibroblast growth factor receptor PD166866 controls negatively the growth of tumor cells in culture.

Authors:  Gianfranco Risuleo; Marina Ciacciarelli; Mauro Castelli; Gaspare Galati
Journal:  J Exp Clin Cancer Res       Date:  2009-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.